BioStar merger makes Cortech instant player in in vitro diagnostics market.
This article was originally published in The Gray Sheet
CORTECH SHIFTING STRATEGIC FOCUS TOWARD POINT-OF-CARE DIAGNOSTICS through acquisition of privately held BioStar, valued at about $18.7 mil. Under a definitive merger agreement announced Dec. 23, Cortech would trade 28.5 mil. new shares of common stock for all of BioStar; Cortech stock closed at 21/32 on Dec. 22. "We believe that this merger will enable us to create one of the premier point-of-care diagnostics companies in the country," BioStar President and CEO Teresa Ayers remarked.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.